Silence Therapeutics (SLN) Gross Profit (2024 - 2026)

Silence Therapeutics has disclosed Gross Profit across 3 years of filings, most recently posting $411000.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at $411000.0, up 367.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $667000.0 (down 96.42% YoY), and the FY2025 annual result was $344000.0, down 98.91% from the prior year.
• Gross Profit came in at $411000.0 for Q1 2026 at Silence Therapeutics, up from $22000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $23.3 million in Q4 2024 to a low of -$2.6 million in Q2 2024.
• The 3-year median for Gross Profit is $95000.0 (2025), against an average of $3.6 million.
• Across the five-year window, Gross Profit sank 99.91% in 2025 and jumped 367.05% in 2026, its largest moves.
• Silence Therapeutics' Gross Profit stood at $23.3 million in 2024, then tumbled by 99.91% to $22000.0 in 2025, then soared by 1768.18% to $411000.0 in 2026.
• The last three Gross Profit figures came in at $411000.0 (Q1 2026), $22000.0 (Q4 2025), and $95000.0 (Q3 2025), per Business Quant data.